Leveraging the Medical Device Tax
Source: MassDevice  (6/15/12)
"Stakeholders should leverage the tax in their projections and negotiations with the industry, especially during mergers and acquisitions, notwithstanding the ongoing push in Washington to repeal the levy." More >

How to Find Small Companies with Big Prospects: Raghuram Selvaraju
Source: George S. Mack of The Life Sciences Report  (6/14/12)
Raghuram "Ram" Selvaraju's professional career started at the Geneva-based biotech firm Serono in 2000, where he discovered the first novel protein candidate developed entirely within the company. He subsequently became the youngest recipient of the company's Inventorship Award for Exceptional Innovation and Creativity. Now an analyst with Aegis Capital Corp., Selvaraju is bringing biotech growth names to his firm's customers. In this exclusive interview with
The Life Sciences Report
Selvaraju shares stock ideas that could return significant gains to investors. More >

Tiny the Mouse Takes a Giant Step for Mankind
Source: Severine Kirchner, The Daily Reckoning  (6/14/12)
"Don't be fooled by this little mouse's name, because what Tiny represents in the world of regenerative medicine is anything but tiny." More >

Five Ways to Spot the Next Hot Biotech Stock
Source: Keith Fitz-Gerald, Money Morning  (6/13/12)
"For all their potential, biotech stocks remain among the most challenging for investors to identify, select and earn money on. However, with a little bit of guidance you can narrow your list to the stocks with the highest likely upside." More >

High Court to Hear Amgen's 'Fraud-on-the-Market' Case
Source: Mari Serebrov, BioWorld Today  (6/12/12)
"The biotech industry is hoping the Supreme Court will do what Congress hasn't been able to do—give companies a fighting chance against class-action shareholder lawsuits claiming 'fraud on the market.'" More >

Human Genome Returning 13% with Bet on Glaxo Sweetener
Source: Bloomberg, Tara Lachapelle  (6/12/12)
"Glaxo, which collaborates with Human Genome on three drugs, may raise its bid to $15 a share to overcome the company's poison pill." More >

ETF Trading Report: Pharma, Consumer ETFs in Focus
Source: Eric Dutram, Zacks Investment Research  (6/11/12)
"The pharma sector experienced a boost in trading activity to start the week. Volume across the pharma space was high as investors sought exposure to perceived safe havens." More >

A Star Is Born at ASCO 2012
Source: Medical Technology Stock Newsletter  (6/8/12)
"This year's ASCO winners appear to have solid momentum that is allowing them to buck the 'sell ASCO' mantra." More >

Reap Biotech Profits from Overlooked Spaces: Alan Carr
Source: George S. Mack, The Life Sciences Report  (6/7/12)
Within the investment community, the story goes that new antibiotics can't generate big profits and central nervous system (CNS) drugs are too difficult to develop. Investors worry they could be throwing good money after bad. Senior Biotechnology Analyst Alan Carr of Needham & Company refutes these tales and believes that product differentiation provides the formula for success. In this exclusive interview with
The Life Sciences Report,
Carr shares his deep industry knowledge and renders his very best ideas in the CNS, antibiotic, antiviral and metabolic spaces. More >

House Votes to Repeal Medical Device Tax
Source: Washington Post, Ed O'Keefe  (6/7/12)
"The Health Care Cost Reduction Act of 2012 would repeal a 2.3% excise tax on gross sales receipts in excess of $5M for manufacturers and importers of certain medical devices, including defibrillators, pacemakers and prosthetic limbs. Congressional budget officials estimate that the tax would raise nearly $30B in revenue between 2013 and 2022." More >

New Technique Offers Better Understanding of Human Tissues
Source: ScienceDaily   (6/6/12)
"The study is one of the first to explore how this technology, called bimodal dual AC mode microscopy, can improve our understanding of human tissues and biomaterials." More >

New AMA Chief: No Chaos with Court's Health Ruling
Source: Associated Press, Lindsey Tanner  (6/6/12)
"The AMA has supported Obama's health overhaul, though a vocal contingent of doctor-members has urged the group to back off that stance." More >

Six Biotech Stocks Riding the Baby Boomer Wave
Source: Diane Alter, Money Morning  (6/6/12)
"While no one has discovered a cure for Alzheimer's, cancer, Parkinson's or other ailments that come along with old age, several biotech companies are racing to cure a long list of diseases and disorders. The prospects are daunting but the possibilities in the biotech field are literally endless, for patients and investors alike." More >

ASCO 2012: Finally, Progress Reported With Targeted Treatments for Lung Cancer
Source: Anette Breindl, BioWorld  (6/5/12)
"While breast cancer's pink ribbons have become a cottage industry, many of lung cancer's victims—even if they are nonsmokers—are less enthusiastic about being the face of a disease that many people view as self-inflicted. But several presentations at this year's ASCO meeting suggested that scientists are beginning to make inroads into the disease, which kills more patients than breast, prostate and colorectal cancer combined." More >

Autologous Immunotherapy Updates at ASCO Further Define Antitumor Immune Responses
Source: Patricia Dimond, Genetic Engineering and Biotechnology News  (6/4/12)
"Accumulating clinical and immunologic evidence presented at this year's ASCO meeting moved autologous cancer therapeutics further toward meeting the need for less-toxic therapies." More >

Biotech Ideas That Will Change the World: Patrick Cox
Source: George S. Mack, The Life Sciences Report  (5/31/12)
For Patrick Cox, disruptive technologies drive change and harbor opportunity. Cox, editor of Breakthrough Technology Alert and Technology Profits Confidential, and a contributor to The Daily Reckoning, strives to find novel ideas in small-cap companies that are off investors' radar screens. In this exclusive interview with The Life Sciences Report, Cox reveals—in his characteristic none-too-shy style—where he believes investors can find huge returns in biotech companies that will change the world. More >

3 Biotech Stocks That Could Change the World
Source: George S. Mack, The Life Sciences Report  (5/31/12)
Every investor is in search of a breakthrough that will change the world. Patrick Cox has seen it all before, as an insider at Netscape Communications before it was acquired by AOL Inc. (NYSE: AOL) at the end of 1998, and before Microsoft Corp. (NASDAQ: MSFT) ever noticed that the world was shifting under its feet. The browser revolution began with the straightforward idea that all computer operating systems could be networked with seamless cross-platform ease. I recently interviewed Cox, now editor of Breakthrough Technology Alert and Technology Profits Confidential, for the story "Biotech Ideas That Will Change the World" in The Life Sciences Report. He sees a new revolution in progress as stem cell technologies and targeted therapies begin to change the entire paradigm of medical practice. More >

House Votes to Approve FDA Funding Bill
Source: Reuters, Anna Yukhananov  (5/30/12)
"The House of Representatives approved a bill that helps fund the Food and Drug Administration and gives it new authority to prevent drug shortages and speed reviews of medical devices." More >

The 152-Year-Old Brain That Changed the Course of Science
Source: Michael Robinson, Money Morning  (5/29/12)
"An accident a century and a half ago has provided a major link to one of the biggest quests in all of science: getting a complete map of the human brain. Once we have that under our belts, you will see one biotech breakthrough after another after another." More >

M&A Likely to Grow with Deal Premiums and Multiples
Source: Alex Philippidis, Genetic Engineering & Biotech News  (5/28/12)
"The bad news for the IPO market should be good news for biopharma M&A this year. Big companies are increasingly willing to pay a big price for a larger presence, notably specialty pharma and diagnostics." More >

'Arise and Walk!'—A Miracle Cure in the Works
Source: Severine Kirchner, Daily Reckoning  (5/28/12)
"Stem cell therapies are on the threshold of making truly miraculous cures an everyday event." More >

ASCO Abstracts 2012
Source: Market Technology Stock Newsletter  (5/25/12)
"The ASCO abstracts came out last week and a review of the massive data dump has revealed a few nuggets." More >

Make Friends with Companion Diagnostics to Bolster Your Biotech Portfolio: Stephen Brozak
Source: George S. Mack of The Life Sciences Report  (5/24/12)
Hitting just the right target and engineering cells to perform certain tasks will unlock the deep secrets of biology and change the entire paradigm of medicine, says WBB Securities President and Managing Partner Stephen Brozak. He is not picking the ultimate winners just yet, but he is playing stem cell and personalized medicine developers as a diversified portfolio, knowing that successes will overpower the also-rans. In this exclusive interview with The Life Sciences Report, Brozak shares names from his list of finalists. More >

It's Like Having a 'Fountain of Youth' in a Bottle
Source: Michael A. Robinson, Money Morning  (5/23/12)
"Scientists have tweaked a benign virus so that it can extend the lifespan of mammals by up to 24%. And if taken at the right time, this modified virus could extend the average life expectancy for an American to roughly 98 years from the current 78.5." More >

Superior Biotechnology Leads to Superior Drugs
Source: Ray Blanco, The Daily Reckoning  (5/23/12)
"Revolutions in our understanding of the genome and proteome are opening up new pathways toward vanquishing the cancer foe." More >